188 related articles for article (PubMed ID: 8297739)
1. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
Ardizzoni A; Venturini M; Sertoli MR; Giannessi PG; Brema F; Danova M; Testore F; Mariani GL; Pennucci MC; Queirolo P
Br J Cancer; 1994 Feb; 69(2):385-91. PubMed ID: 8297739
[TBL] [Abstract][Full Text] [Related]
2. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
6. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
Stöger H; Samonigg H; Krainer M; Ploszczynski M; Nirnberger G; Maca S; Hehenwarter W; Wirth M; Schüller J; Vavra N; Scheithauer W; Kornek G; Stierer M; Zielinski CC
Eur J Cancer; 1998 Mar; 34(4):482-8. PubMed ID: 9713297
[TBL] [Abstract][Full Text] [Related]
7. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
9. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
[TBL] [Abstract][Full Text] [Related]
10. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer.
O'Shaughnessy JA; Tolcher A; Riseberg D; Venzon D; Zujewski J; Noone M; Gossard M; Danforth D; Jacobson J; Chang V; Goldspiel B; Keegan P; Giusti R; Cowan KH
Blood; 1996 Mar; 87(6):2205-11. PubMed ID: 8630380
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
[TBL] [Abstract][Full Text] [Related]
12. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
14. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
15. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer.
Osborne CK; Sunderland MC; Neidhart JA; Ravdin PM; Abeloff MD
Ann Oncol; 1994 Jan; 5(1):43-7. PubMed ID: 8172792
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
Hoekman K; Wagstaff J; van Groeningen CJ; Vermorken JB; Boven E; Pinedo HM
J Natl Cancer Inst; 1991 Nov; 83(21):1546-53. PubMed ID: 1960751
[TBL] [Abstract][Full Text] [Related]
17. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
[TBL] [Abstract][Full Text] [Related]
18. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
Ardizzoni A; Venturini M; Crinò L; Sertoli MR; Bruzzi P; Pennucci MC; Mariani GL; Garrone O; Bracarda S; Rosso R
Eur J Cancer; 1993; 29A(5):687-92. PubMed ID: 8385970
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
Honkoop AH; Hoekman K; Wagstaff J; van Groeningen CJ; Vermorken JB; Boven E; Pinedo HM
Br J Cancer; 1996 Oct; 74(7):1132-6. PubMed ID: 8855987
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
